Nkarta, Inc. Common Stock
NKTXNkarta, Inc. is a biotechnology company focused on developing allogeneic CAR NK (natural killer) cell therapies for cancer treatment. Leveraging its proprietary cell engineering platform, Nkarta aims to create off-the-shelf immunotherapies to improve efficacy and safety for patients with various cancers.
Company News
Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases. The company reported ongoing enrollment in ...
The idiopathic membranous nephropathy (IMN) market is expected to grow from USD 130 million in 2025 to USD 1 billion by 2036, driven by rising disease prevalence, improved diagnostics, and emerging targeted therapies. Multiple pharmaceutical companies are advancing novel treatments including SNP-ACTH (1-39) Gel, zanubrutinib, obinutuzumab, and po...
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered NK cell therapies for autoimmune diseases, announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 2, 2026 in Boston, and the Leerink Global Healthcare Conference on March 10, 2026 in Mia...
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.
Nkarta, Inc., a biopharmaceutical company developing engineered natural killer (NK) cell therapies, announced its participation in the 7th Annual Evercore HealthCONx Conference on December 4, 2024.
